N-tBoc-L-leucylglycine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-tBoc-L-leucylglycine
• 英文别名: 2-[[4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]amino]acetic Acid
• 化学式: C₁₃H₂₄N₂O₅
• 分子量: 288.344
• InChiKey: NRXDUMDULDHIEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-tBoc-L-leucylglycine 、 五氟苯酚 、 N,N'-二环己基碳二亚胺 以 乙酸乙酯 为溶剂， 反应 12.0h， 生成 、 N,N-二环己脲
  参考文献：
  名称：

  Tumour targeting prodrugs activated by metallo matrixproteinases

  摘要：

  化合物的结构关系示例（8）与其潜在代谢产物的关系 1. 括号中的数字表示规范中的示例 化合物具有通式（I），其中（A）是包含杂环环、碳环环和融合环系统中的一个或多个的基团，该环或环系统通过作用于核酸或蛋白靶标而对化合物的生物活性至关重要；（B）是直接连接到环系统的二价间隔分子；n是整数0或1；（X）是含有可被基质金属蛋白酶酶作用而可裂解的酰胺键的一价基团，从而产生通式（II）的化合物，其中通式（II）的化合物的生物活性效力比通式（I）的化合物增加。

  公开号：

  US20040248765A1

文献信息

• RILUZOLE PRODRUGS AND THEIR USE
  申请人：Biohaven Pharmaceutical Holding Company Ltd.

  公开号：US20180036290A1

  公开（公告）日：2018-02-08

  Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

  本发明的制药组合物包括替代利鲁唑前药，通过释放利鲁唑治疗包括黑色素瘤、乳腺癌、脑癌和前列腺癌等癌症。利鲁唑的前药具有增强的肝代谢稳定性，并通过口服途径输送到全身循环中，然后通过酶促或一般的生物物理释放过程在血浆中裂解释放利鲁唑。
• Process for producing sequential polyamino acid resin
  申请人：NITTO BOSEKI CO., LTD.

  公开号：EP0138605A2

  公开（公告）日：1985-04-24

  A sequential polyamino acid resin having a remarkably high molecular weight and special amino acid sequence as repeating unit in the resin can be produced by conduction polycondensation of a dipeptide active ester acid salt in an aprotic polar solvent in the presence of a tertiary amine and phosphorus pentoxide.

  在叔胺和五氧化二磷存在下，二肽活性酯酸盐在非烷基极性溶剂中通过传导缩聚反应，可生产出具有极高分子量和特殊氨基酸序列作为树脂重复单元的连续聚氨基酸树脂。
• PHARMACEUTICAL COMPOSITIONS COMPRISING RILUZOLE PRODRUGS
  申请人：Biohaven Pharmaceutical Holding Company Ltd.

  公开号：EP4011870A1

  公开（公告）日：2022-06-15

  Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

  本发明的药物组合物包括取代的利鲁唑原药，可通过释放利鲁唑治疗癌症，包括黑色素瘤、乳腺癌、脑癌和前列腺癌。利鲁唑原药对肝脏代谢的稳定性增强，通过口服进入全身循环，然后通过酶或一般生物物理释放过程裂解，在血浆中释放利鲁唑。
• Prodrugs of riluzole and their method of use
  申请人：Biohaven Pharmaceutical Holding Company Ltd.

  公开号：US10639298B2

  公开（公告）日：2020-05-05

  Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

  本发明的药物组合物包括取代的利鲁唑原药，可通过释放利鲁唑治疗癌症，包括黑色素瘤、乳腺癌、脑癌和前列腺癌。利鲁唑原药对肝脏代谢的稳定性增强，通过口服进入全身循环，然后通过酶或一般生物物理释放过程裂解，在血浆中释放利鲁唑。
• Riluzole prodrugs and their use
  申请人：Biohaven Therapeutics Ltd.

  公开号：US10905681B2

  公开（公告）日：2021-02-02

  Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

  本发明的药物组合物包括取代的利鲁唑原药，可通过释放利鲁唑治疗癌症，包括黑色素瘤、乳腺癌、脑癌和前列腺癌。利鲁唑原药对肝脏代谢的稳定性增强，通过口服进入全身循环，然后通过酶或一般生物物理释放过程裂解，在血浆中释放利鲁唑。